Comirnaty

Global information about COMIRNATY

Regulatory approval has been granted in several countries worldwide for the product COMIRNATY COVID‑19 mRNA Vaccine (nucleoside modified) (Pfizer‑BioNTech COVID‑19 Vaccine in several countries) for active immunisation to prevent COVID‑19 caused by SARS‑CoV‑2, in children aged 6 months to 11 years and individuals 12 years of age and older. 

Please select your country to ensure you access the information specific to your location.

Information about COMIRNATY COVID‑19 mRNA Vaccine (nucleoside modified) is only available for certain countries. This site will be updated as more information becomes available.